AMLX Stock — Amylyx Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$29.50

Market cap

$3,701.0M

Cash

$768.1M

Enterprise value

$2,932.9M

Balance sheet

Cash	$768.1M
Debt	$0.0M
Net cash	$768.1M
Enterprise value	$2,932.9M
Basic shares	128.6M shares
Fully diluted shares	132.3M shares
Fully diluted market cap	$3,903.1M
Cash per share	$5.97
Quarterly burn	$31.4M
Cash runway	23.0 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

111.4M

Pre-funded warrants

0.0M

Options

11.3M

RSUs

5.9M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

3.7M

FDSO

132.3M

Cap table as of 2026-06-30.

Price history

Loading AMLX daily closes…

Loading price history…

Next catalyst

avexitide · Dec 1-31 · guided in 24d

Recently reported

avexitide Phase 3 Positive · 2026-08-18

LUCIDITY · post-bariatric hypoglycemia

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDDec 1-31 in 24d	avexitide NDA submission for post-bariatric hypoglycemia	Not disclosed	post-bariatric hypoglycemia	end of 2026
Mar 15 - Apr 26 in 4 mo	AMX0114	Phase 1	ALS	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

avexitide

Phase 3 · Active Modality: GLP-1 receptor antagonist

Target GLP-1 receptor

Indications

Post-bariatric hypoglycemia (PBH) (Phase 3)
Congenital hyperinsulinism (congenital HI) (Stage not disclosed)

Status note Lead investigational asset; first-in-class GLP-1 receptor antagonist. LUCIDITY (NCT06747468): 78-participant Phase 3 in PBH post-RYGB at 21 U.S. sites. Expanded Access Program initiated May 2026 for U.S. adults with PBH post-RYGB.

AMX0035

Phase 2 · Active Modality: oral fixed-dose combination of sodium phenylbutyrate and taurursodiol

Target ER stress and mitochondrial dysfunction

Indications

Wolfram syndrome (Phase 2)
Progressive supranuclear palsy (PSP) (Phase 2)

Status note HELIOS open-label Phase 2 in Wolfram syndrome ongoing; company working with FDA on a Phase 3. Phase 2b/3 in PSP discontinued and winding down.

AMX0114

Phase 1 · Active Modality: antisense oligonucleotide (ASO)

Target CAPN2 (calpain-2)

Indications

Amyotrophic lateral sclerosis (ALS) (Phase 1)

Status note LUMINA (NCT06665165): multinational multiple-ascending-dose Phase 1 in ALS; Cohort 1 biomarker data presented Jun 2026. FDA Fast Track Designation.

AMX0318

Preclinical · Active Modality: GLP-1 receptor antagonist (long-acting)

Target GLP-1 receptor

Partnerships Gubra A/S: collaboration and license agreement (Dec 2024) for long-acting GLP-1 receptor antagonist R&D; second research collaboration Jul 2026 for a rare endocrine disease

Indications

PBH and other rare diseases (Preclinical)

Status note Selected as development candidate Jan 2026 after preclinical evaluation; IND-enabling studies planned/ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Avexitide
Lead indication	Post Bariatric Hypoglycemia
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06747468	Phase 3	Active, not recruiting	Sponsor	AMLX	—	Post Bariatric Hypoglycemia	—
NCT05676034	Phase 2	Active, not recruiting	Sponsor	AMLX	—	Wolfram Syndrome	—
NCT06665165	Phase 1	Recruiting	Sponsor	AMLX	—	ALS	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Amylyx Pharmaceuticals Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	8,334,882	+50,000	2.32%	2026-08-14
Boxer Capital	800,000	no change	1.08%	2026-08-14
Great Point Partners	700,000	-1,050,000	2.96%	2026-08-14
ADAR1 Capital Management	494,378	-506,226	0.42%	2026-08-14
Logos Global Management	350,000	-350,000	0.27%	2026-08-14
Cormorant Asset Management	200,000	-150,000	0.18%	2026-08-14
OrbiMed Advisors	183,400	+183,400	0.06%	2026-08-14
Ikarian Capital	117,500	+117,500	0.35%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

AMLX — Amylyx Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

AMLX — Amylyx Pharmaceuticals Inc.